Poxel SA
14
0
0
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
14.3%
2 terminated/withdrawn out of 14 trials
85.7%
-0.8% vs industry average
0%
0 trials in Phase 3/4
17%
2 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Study to Assess PXL770 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)
Role: lead
Study to Assess PXL065 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)
Role: lead
Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)
Role: lead
Study to Assess the Safety, Tolerability, and Pharmacokinetics of PXL770 in Healthy Subjects.
Role: lead
A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD
Role: lead
A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD
Role: lead
Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects
Role: lead
Pharmacokinetics and Metabolism of (14C)-Labelled PXL770
Role: lead
Bioequivalence of Imeglimin Tablet Formulations
Role: lead
Effect of Cimetidine on the PK of Imeglimin
Role: lead
Safety, Tolerability and PK of PXL770 in Healthy Male Subjects
Role: lead
Effect of Imeglimin on QT/QTc Intervals in Healthy Subjects
Role: lead
Safety, Tolerability and PK of Imeglimin in Japanese Volunteers
Role: lead
A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes
Role: lead
All 14 trials loaded